ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference
May 15, 2019 16:01 ET
|
ChromaDex Corporation
LOS ANGELES, May 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the...
ChromaDex Corporation Reports First Quarter 2019 Financial Results
May 09, 2019 16:01 ET
|
ChromaDex Corporation
- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net sales, higher gross...
ChromaDex Announces $10 Million Issuance of Convertible Notes
May 09, 2019 08:20 ET
|
ChromaDex Corporation
LOS ANGELES, May 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a...
ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
May 02, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, May 02, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its financial...
ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies
April 24, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp....
ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada
April 15, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with...
New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)
April 09, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, April 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin...
Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XP’s Sixth Annual Biohacking Conference
April 03, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, April 03, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world’s foremost authority on NAD metabolism and...
ChromaDex to Present at the 31st Annual ROTH Conference
March 11, 2019 16:01 ET
|
ChromaDex Corporation
LOS ANGELES, March 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial...
ChromaDex Brings TRU NIAGEN® to SXSW® 2019
March 08, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, March 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of...